Investigational drug may increase survival for some patients with advanced melanoma

An experimental drug aimed at restoring the immune system’s ability to spot and attack cancer-halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multi-site, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

Fuente : http://www.eurekalert.org/pub_releases/2014-03/jhm…